AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
TELA Bio, Inc.
Video analysis: TELA
All videosNo video analysis for this stock yet. Request one from our team.
News: TELA
TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis
Baxter International (NYSE: BAX - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Volatility and Risk Baxter International has a beta
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company's newly-hired Chief Executive Officer, Heather Getz, with a grant date of August 3, 2026 (the "Getz Grant Date"). The stock options consist of (i) stock options to purchase 1,365,000 shares of common stock (the “Standard Options”) and (ii) premium-priced stock options to purchase 1,005,000 shares of common stock (the “Premium-Options”). Additionally, the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 95,500 shares of its common stock to 11 newly-hired employees, with a grant date of August 4, 2026. The stock options and the restricted stock units discussed above were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Ms. Getz's and each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today.
TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference.
TELA Bio to Announce Second Quarter 2026 Financial Results
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2026 financial results on Monday, August 10, 2026.
